「dos」の検索結果

Configures AWS Shield Advanced for enhanced Distributed Denial of Service (DDoS) protection: subscribing accounts and adding resource protections, enabling automatic application layer (layer 7) mitigation through AWS WAF, configuring health-based detection with Route 53 health checks, setting up Shield Response Team (SRT) access and proactive engagement, reviewing DDoS events and requesting cost protection credits, and aggregating resources into protection groups. Applicable when the user wants stronger DDoS protection for internet-facing resources (CloudFront, Application or Network Load Balancers, Elastic IP addresses, Global Accelerator, or Route 53 hosted zones), wants expert help during an attack, or wants to recover attack-driven scaling charges. Routes to the right per-task procedure in references. Not applicable for authoring AWS WAF rules (waf skill), creating Route 53 health checks (route53 skill), or org-wide Shield Advanced rollout with Firewall Manager (firewallmanager skill).

日本語の概要は準備中です。原文の説明を表示しています。

Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.

日本語の概要は準備中です。原文の説明を表示しています。

Use when the user asks what is pending, what to do next, or to list todos (optionally filtered by area). Lists pending todos, loads full context for the selected one, and routes to work now, add to a phase, brainstorm, or create a phase.

日本語の概要は準備中です。原文の説明を表示しています。

This skill should be used when managing the file-based todo tracking system in the todos/ directory. It provides workflows for creating todos, managing status and dependencies, conducting triage, and integrating with slash commands and code review processes.

日本語の概要は準備中です。原文の説明を表示しています。

Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.

日本語の概要は準備中です。原文の説明を表示しています。

Verifica la paridad de internacionalización — que cada clave de traducción exista en todos los idiomas y que no haya cadenas visibles para la persona usuaria codificadas de forma fija — siguiendo las convenciones de i18n del proyecto. Úsalo cuando la persona pida revisar las traducciones, verificar la paridad entre idiomas, encontrar cadenas faltantes/codificadas o auditar la i18n (p. ej. "revisa la i18n", "¿están todos los idiomas sincronizados?").

日本語の概要は準備中です。原文の説明を表示しています。

Audita una vista o componente frente al design system en lo que un script no puede comprobar — estados de interacción, los cuatro estados de datos, primitivas nativas frente a componentes reinventados y jerarquía visual. Úsalo cuando la persona pida revisar el cumplimiento del design system o si un componente sigue las guías (p. ej. "¿esta tarjeta sigue nuestro sistema?", "audita la vista de ajustes").

日本語の概要は準備中です。原文の説明を表示しています。

Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.

日本語の概要は準備中です。原文の説明を表示しています。

Dose-response modeling — EC50 estimation, curve fitting, synergy analysis, and benchmark-dose methods.

日本語の概要は準備中です。原文の説明を表示しています。

Calculates salmon calcitonin dose based on patient weight for rapid calcium lowering in hypercalcemia of malignancy. Triggered when a clinician considers rapid calcium lowering and asks about weight‑based calcitonin dosing.

日本語の概要は準備中です。原文の説明を表示しています。

This skill determines whether confirmatory testing can be omitted after a positive aldosterone-to-renin ratio (ARR) in patients with suspected primary aldosteronism. It is applied when a patient exhibits spontaneous hypokalemia, undetectable renin, and a plasma aldosterone concentration ≥20 ng/dL (550 pmol/L).

日本語の概要は準備中です。原文の説明を表示しています。

This skill interprets the oral sodium loading test for primary aldosteronism by evaluating 24‑hour urinary aldosterone excretion after a high‑sodium diet. Use when reviewing results of an "oral sodium loading test" for PA diagnosis; trigger phrases include "urinary aldosterone excretion ≤10 g/24 h" (PA unlikely) or "≥12 g/24 h (Mayo) / ≥14 g/24 h (Cleveland)" (PA highly likely).

日本語の概要は準備中です。原文の説明を表示しています。

Suggests using a low-dose (1 µg) corticotropin stimulation test to diagnose primary adrenal insufficiency when the standard 250 µg corticotropin is unavailable due to drug shortage. Consider this approach when clinicians encounter a corticotropin shortage or when the standard dose cannot be obtained.

日本語の概要は準備中です。原文の説明を表示しています。

Evaluates likelihood of primary aldosteronism by measuring plasma aldosterone suppression after oral captopril; normal suppression ≥30% makes PA unlikely, while lack of suppression with persistently suppressed plasma renin activity suggests PA. Use when assessing captopril challenge test (CCT) results for PA diagnosis in patients with positive aldosterone-to-renin ratio.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends fludrocortisone 100 µg daily for children with primary adrenal insufficiency and confirmed aldosterone deficiency; for infants under 12 months, adds sodium chloride supplementation. Triggered by PAI with aldosterone deficiency, evidenced by salt craving, hyponatremia, hyperkalemia, or elevated renin with low aldosterone.

日本語の概要は準備中です。原文の説明を表示しています。

Interprets the saline infusion test (SIT) to assess the probability of primary aldosteronism when a patient has a positive aldosterone-to-renin ratio (ARR) and requires confirmatory testing. Triggers include evaluating post‑infusion plasma aldosterone concentration (PAC) after a positive ARR, hypertension work‑up, or when deciding whether to proceed to adrenal venous sampling (AVS).

日本語の概要は準備中です。原文の説明を表示しています。

Determines whether to perform adrenal venous sampling (AVS) to lateralize aldosterone excess in patients with confirmed primary aldosteronism (PA) who are being evaluated for surgical treatment. Indicated when surgery is feasible and desired by the patient, or when subtype workup is planned for a surgical candidate, especially in those younger than 35 years with spontaneous hypokalemia, marked aldosterone excess, and unilateral adrenal lesions on CT.

日本語の概要は準備中です。原文の説明を表示しています。

Determines unilateral vs bilateral aldosterone excess based on cortisol-corrected aldosterone ratios from adrenal venous sampling, with ratio >4:1 indicating unilateral excess, ratio 3:1 suggestive of bilateral hypersecretion, and interpretation dependent on cosyntropin stimulation protocol used during sampling. Use when analyzing AVS results to guide surgical vs medical treatment decisions; triggers include 'AVS lateralization ratio', 'cosyntropin-stimulated AVS', 'aldosterone-to-cortisol ratio >4:1', and 'ratio 3:1 suggestive of bilateral disease'.

日本語の概要は準備中です。原文の説明を表示しています。

Determines if primary aldosteronism is confirmed based on upright plasma aldosterone ≤6 ng/dL (170 nmol/L) on day 4 at 10 AM of fludrocortisone suppression test, provided plasma renin activity ≥1 ng/mL/h and plasma cortisol concentration lower than the 7 AM value to exclude ACTH confounding. Use when reviewing FST results to diagnose PA; triggers include "FST", "upright aldosterone ≤6 ng/dL", "PRA ≥1 ng/mL/h", and "cortisol drop".

日本語の概要は準備中です。原文の説明を表示しています。

The Endocrine Society recommends a standard-dose corticotropin (ACTH) stimulation test to confirm primary adrenal insufficiency when clinical suspicion arises from symptoms such as hypotension, hyponatremia, hyperkalemia, or unexplained fatigue. Dosing is weight/age based: 250 µg for adults and children ≥2 years, 15 µg/kg for infants, and 125 µg for children <2 years.

日本語の概要は準備中です。原文の説明を表示しています。

Teaches AI patients about stress-dosing and emergency glucocorticoid administration; instructs to obtain emergency card/bracelet/necklace and kit with injectable high-dose GC. Triggers when counseling any patient with adrenal insufficiency (e.g., "Use when counseling patient with adrenal insufficiency...").

日本語の概要は準備中です。原文の説明を表示しています。

Projete esquemas de banco de dados robustos e escaláveis para SQL e NoSQL. Fornece diretrizes de normalização, estratégias de indexação, padrões de migração, design de restrições e otimização de desempenho. Garante integridade de dados, desempenho de consultas e modelos de dados mantíveis.

日本語の概要は準備中です。原文の説明を表示しています。

Arquiteto de banco de dados especializado em design de camada de dados do zero, seleção de tecnologia, modelagem de schemas e arquiteturas de bancos de dados escaláveis.

日本語の概要は準備中です。原文の説明を表示しています。

Domine SQL moderno com bancos de dados cloud-native, otimização OLTP/OLAP e técnicas avançadas de query. Especialista em tuning de performance, modelagem de dados e sistemas analíticos híbridos.

日本語の概要は準備中です。原文の説明を表示しています。